TerrAscend (TSNDF) Asset Writedowns and Impairment (2021 - 2026)
TerrAscend's (TSNDF) quarterly Asset Writedowns and Impairment came in at $239000.0 in Q1 2026, down 50.21% year-on-year from $480000.0 in Q1 2025, and down 64.7% on a QoQ basis from $677000.0 in Q4 2025.
TerrAscend (TSNDF) Asset Writedowns and Impairment (2021 - 2026) Analysis & Trends
TerrAscend (TSNDF) has 6 years of Asset Writedowns and Impairment data on file, last reported at $239000.0 in Q1 2026.
- On a quarterly basis, Asset Writedowns and Impairment fell 50.21% year-over-year to $239000.0 in Q1 2026; TTM through Mar 2026 was $1.4 million, a 70.56% decrease from a year earlier, with the FY2025 full-year figure at $1.7 million, down 45.48% from the prior year.
- Asset Writedowns and Impairment for Q1 2026 stood at $239000.0, down from $677000.0 in the prior quarter.
- Over the last five years, Asset Writedowns and Impairment for TSNDF reached as high as $152.9 million in Q3 2022 and fell as low as -$7.3 million in Q4 2022.
- Historically, Asset Writedowns and Impairment has averaged $9.2 million across 5 years, with a median of $314000.0 in 2025.
- On a YoY basis, Asset Writedowns and Impairment climbed as much as 39314.43% in 2022 and fell as far as 572.06% in 2022.
- Year by year, Asset Writedowns and Impairment stood at -$7.3 million in 2022, then jumped by 90.04% to -$728000.0 in 2023, then surged by 675.55% to $4.2 million in 2024, then sank by 83.84% to $677000.0 in 2025, then sank by 64.7% to $239000.0 in 2026.
- Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were $239000.0 in Q1 2026, $677000.0 in Q4 2025, and $314000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | TerrAscend | 160.44 Mn | 162.98 Mn | 34.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 239,000.00 |
| Mar 31, 2026 | 239,000.00 |
| Dec 31, 2025 | 677,000.00 |
| Dec 31, 2025 | 677,000.00 |
| Sep 30, 2025 | 314,000.00 |
| Sep 30, 2025 | 314,000.00 |
| Jun 30, 2025 | 193,000.00 |
| Jun 30, 2025 | 193,000.00 |
| Mar 31, 2025 | 480,000.00 |
| Mar 31, 2025 | 480,000.00 |
| Dec 31, 2024 | 4.19 Mn |
| Dec 31, 2024 | 4.19 Mn |
| Sep 30, 2024 | 183,000.00 |
| Sep 30, 2024 | 183,000.00 |
| Jun 30, 2024 | -20,000.00 |
| Jun 30, 2024 | -20,000.00 |
| Mar 31, 2024 | 2.44 Mn |
| Mar 31, 2024 | 2.44 Mn |
| Dec 31, 2023 | -728,000.00 |
| Dec 31, 2023 | -728,000.00 |